Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study.
FOLFOXIRI therapy
anti-EGFR antibodies
anti-VEGF antibodies
metastatic colorectal cancer
triplet
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
01 Feb 2019
01 Feb 2019
Historique:
received:
02
11
2018
accepted:
11
01
2019
entrez:
26
2
2019
pubmed:
26
2
2019
medline:
26
2
2019
Statut:
epublish
Résumé
FOLFOXIRI plus bevacizumab has a promising efficacy as first-line systemic chemotherapy for metastatic colorectal cancer (mCRC). This study aimed to evaluate the safety and effectiveness of FOLFOXIRI plus antibodies. Fifty-five patients were enrolled (median age: 60 years, males: 25, females: 30). Twenty-six subjects had RAS mutations and 29 had RAS wild-type. Anti-VEGF and anti-EGFR antibodies were administered to 38 and 17 patients, respectively. The most common severe adverse event was neutropenia (51%). The overall response rate (ORR) was 69% (55% with anti-VEGF antibodies and 100% with anti-EGFR antibodies; We retrospectively collected data from mCRC patients treated with FOLFOXIRI plus antibodies between March 2014 and December 2017. FOLFOXIRI plus antibody therapy was effective in patients with mCRC. The response rate was higher in patients treated with anti-EGFR antibodies than in those treated with anti-VEGF antibodies.
Identifiants
pubmed: 30800219
doi: 10.18632/oncotarget.26626
pii: 26626
pmc: PMC6383688
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1070-1084Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Références
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):197-202
pubmed: 16767931
Pharmacogenet Genomics. 2007 Jul;17(7):497-504
pubmed: 17558305
J Clin Oncol. 2009 Dec 10;27(35):5931-7
pubmed: 19884549
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
J Pathol. 2013 Feb;229(3):441-8
pubmed: 23165447
Ann Oncol. 2013 Aug;24(8):2062-7
pubmed: 23666916
Ann Oncol. 2014 Oct;25(10):1995-2001
pubmed: 25057166
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110
Ann Oncol. 2018 Mar 1;29(3):624-631
pubmed: 29293874
JAMA Oncol. 2018 Apr 1;4(4):529-536
pubmed: 29450468
Int J Clin Oncol. 2018 Jun;23(3):490-496
pubmed: 29464396
Clin Colorectal Cancer. 2018 Jun;17(2):147-155
pubmed: 29530335
Oncotarget. 2018 Apr 10;9(27):18811-18820
pubmed: 29721163